ActoveginАктовегин
What is it?
A deproteinized preparation derived from calf blood. It is a biological mixture rather than a single defined peptide, and is distinct from brain-derived preparations such as Cerebrolysin. It has been investigated in diabetic neuropathy and post-stroke cognitive impairment.
Identity / background source ↗
Research context
Clinical research in diabetic polyneuropathy and post-stroke cognitive impairment. Proposed metabolic effects do not establish protection from hypoxia, enhanced performance or general tissue regeneration.
- Working classification
- Deproteinized blood-derived preparation
- Research collection
- Related nootropics & combinations · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Two randomized trials and a stroke systematic review linked below
- Study methods
- —Mixed endpoints; statistical and clinical significance distinguished
- Independent replication
- —Stroke review reuses ARTEMIDA; independent confirmation remains needed
- Source access
- —Indexed abstracts with links to original publications
- Safety evidence
- —Stroke safety imbalance and uncertain benefit require attention; long-term safety not established here
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Linked sources
Explore the research map and unresolved leads ↗
Actovegin in the management of patients after ischemic stroke: A systematic review.
Deproteinized calf-blood derivative · Journal publication
la Fleur P, Baizhaxynova A, Reynen E, Kaunelis D, Galiyeva D · PloS one
The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.
- Population / setting
- Five controlled studies after ischemic stroke; one randomized trial and four observational studies
- What was checked
- Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Limitations & review scope
- Heterogeneous evidence precluded meta-analysis. This review includes ARTEMIDA and is not an independent additional trial.
Source checked 2026-09-30. This is a source-linked record, not a completed evidence review.
ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.
Deproteinized calf-blood derivative · Journal publication
Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD · Stroke
The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.
- Population / setting
- 503 patients aged 60 or older after ischemic stroke; ARTEMIDA
- What was checked
- Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Limitations & review scope
- Clinical importance and replication remain unresolved. The safety imbalance cannot establish causation or be dismissed as proof of safety. Disease-specific results do not establish healthy-person enhancement.
Source checked 2026-09-30. This is a source-linked record, not a completed evidence review.
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.
Deproteinized calf-blood derivative · Journal publication
Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I · Diabetes care
Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.
- Population / setting
- 567 treated participants with type 2 diabetes and symptomatic polyneuropathy
- What was checked
- Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Limitations & review scope
- Endpoint timing matters; these findings do not establish general nerve regeneration or benefit in healthy people. No difference in adverse-event incidence was reported during this trial.
Source checked 2026-09-30. This is a source-linked record, not a completed evidence review.